8-K: Grown Rogue Enters New York Market via PharmaCann Deal

Grown Rogue International Inc. has taken initial steps to acquire PharmaCann Inc.'s New York assets through a joint venture, securing interim operations and funding.

Summary

• Grown Rogue International Inc. has formed a joint venture, Grown Rogue New York, LLC (GRNY), with a capital partner to enter the New York cannabis market.
• GRNY is 51% owned by Grown Rogue and 49% by the capital partner, who invested $10 million for a preferred equity interest.
• The company is planning to acquire the New York license and assets of PharmaCann Inc. (PCNY), including a cultivation facility and four dispensaries.
• Interim agreements are in place for GRNY to manage PCNY's operations, including a Goods and Services Agreement and a loan of up to $9 million to PCNY.
• The capital partner has also committed $5 million under a drawable term loan and will receive 300,000 subordinate voting shares as a commitment fee.
• The planned acquisition is expected to be finalized within approximately four weeks, subject to regulatory approvals.
• Grown Rogue anticipates cost savings of approximately $20 million annually and expects the New York operations to become cash flow positive within nine months.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strategic expansion and financial partnership, though with inherent risks associated with market entry and regulatory approvals.

Positives

• Strategic entry into the significant New York cannabis market.
• Formation of a joint venture with a capital partner provides $10 million in preferred equity and a $5 million committed term loan.
• Secured interim operational control of PharmaCann's New York assets, including a cultivation facility and four dispensaries.
• Anticipated annual cost savings of approximately $20 million.
• Projected to achieve after-tax operating cash flow positive within nine months and $600,000 monthly cash flow within 18 months.
• Preserves PCNY's operations and team, avoiding significant job losses and operational shutdown.
• The capital partner's investment structure allows for limited balance sheet risk for Grown Rogue.
• Potential for high returns on incremental invested capital, exceeding 75%.

Negatives

• The preferred equity interest held by the capital partner is convertible into Grown Rogue's subordinate voting shares, potentially causing up to 7% dilution.
• The capital partner receives priority annual distributions of $1 million (year 1) and $2 million (thereafter).
• Dispensaries may experience modest disruption due to reduced first-party product availability during the production ramp-up.
• The transaction is subject to significant regulatory approvals and the finalization of definitive purchase agreements.
• The company's financial statements will experience increased complexity due to the transaction.
• The projected cost savings and cash flow generation are based on management's expectations and assumptions, which may not materialize.
• The term loan carries a 15% interest rate.

Risks

• Failure to execute definitive agreements for the acquisition.
• Inability to obtain required regulatory approvals for the change of control.
• Financing or capital constraints could impact the transaction or operations.
• Delays in restarting or ramping up production at the Hamptonburgh facility.
• Inability to achieve anticipated cost reductions, operating cash flow, or investment returns within the expected time frame.
• Operating losses or higher-than-expected costs.
• Lease, facility, or equipment issues.
• Changes in market pricing or consumer demand in New York.

Future Outlook

Grown Rogue anticipates becoming after-tax operating cash flow positive within nine months and generating approximately $600,000 in after-tax monthly cash flow from operations within 18 months in New York. The company expects to implement cost savings of approximately $20 million annually and achieve returns on incremental invested capital greater than 75%. The acquisition is expected to be finalized within approximately four weeks, subject to regulatory approvals.

Management Comments

• "We believe New York regulators have proactively improved the regulatory framework and enforcement efforts, creating a more vibrant, entrepreneurial-led environment that is actively shifting more of the market's demand through regulated channels."
• "That backdrop, coupled with what we believe is a shortage of quality indoor flower, led us to aggressively pursue entry into the New York market when this opportunity became available."
• "We view this move as transformational for Grown Rogue given the production scale and verticality, while remaining squarely in our wheelhouse: the efficient production of craft-quality flower."
• "The project-based financing structure allows us to pursue this opportunity with limited and prudent balance sheet risk, particularly given the history of the New York market."
• "Our immediate focus is preserving the value of the platform, which includes supporting the four Verilife stores and ramping the production of flower."
• "We believe our New York entry will meet or exceed our criteria of generating returns on incremental invested capital of greater than 75%."
• "With identified cost savings that we expect to implement over the first six months of oversight, we anticipate reducing annual costs by approximately $20 million."
• "We also expect this transaction to create complexity as it flows through our GAAP financials, and we are committed to providing investors with as much transparency as possible into the underlying operating performance of the assets."

Industry Context

StockSavvy.ai notes that Grown Rogue's strategic move into New York aligns with broader industry trends of consolidation and expansion into newly regulated or expanding cannabis markets. The company's focus on craft-quality flower production and efficient operations is a key differentiator in a competitive landscape. The formation of a joint venture with a capital partner is a common strategy to mitigate risk and fund significant market entries.

Comparison to Industry Standards

• The projected returns on incremental invested capital of greater than 75% exceed typical industry benchmarks for mature markets, indicating a potentially high-growth opportunity in New York.
• The anticipated cost savings of $20 million annually are substantial and suggest significant operational inefficiencies in the acquired PharmaCann assets that Grown Rogue aims to rectify.
• The projected nine-month timeline to cash flow positivity is aggressive but achievable if cultivation ramp-up and cost-saving measures are executed effectively, aligning with best-in-class operational turnarounds.
• The average monthly sales of $1.7-2.0 million across four dispensaries are a solid baseline, but the success will depend on Grown Rogue's ability to increase market share and optimize product mix, particularly with first-party products.
• The production capacity of the Hamptonburgh facility, previously over 2,000 lbs/month, positions Grown Rogue to become a significant flower supplier in New York, provided the ramp-up is successful.

Related Party Transactions

• GRNY is a joint venture between Grown Rogue (51%) and a Capital Partner (49%).
• The Capital Partner invested $10 million for preferred equity and committed $5 million for a term loan.
• Grown Rogue will issue 300,000 subordinate voting shares to the Capital Partner as a commitment fee.
• GRNY entered into a Goods and Services Agreement with PCNY to manage day-to-day operations.
• GRNY entered into a Master Lease and Sublease for the Hamptonburgh Facility with PCNY and an affiliate of Innovative Industrial Properties.
• GRNY provided up to $9 million in loans to PCNY.

Stakeholder Impact

• Shareholders: Potential for dilution from conversion of preferred equity, but also potential for significant value creation from New York market entry.
• Employees: Efforts to retain current PCNY team members and rehire former employees aim to minimize negative impact.
• Suppliers: Increased demand for cultivation and operational supplies as production ramps up.
• Creditors: The $9 million loan to PCNY is secured by PCNY's assets, providing some security for GRNY's funding.

Next Steps

• Finalize definitive acquisition documentation with PharmaCann Inc.
• Pursue required regulatory approvals for the acquisition.
• Ramp production at the Hamptonburgh facility.
• Manage and revitalize PCNY's four Verilife dispensaries.
• Implement identified cost savings over the first six months.
• Execute the operational reset and build the business around Grown Rogue's disciplines.
• Potentially pursue alternative debt financing for the $5 million term loan commitment.

Key Dates

Recommendation

The filing details a significant strategic expansion into a key market with strong financial backing and promising projections. However, the inherent risks associated with regulatory approvals, integration challenges, potential dilution, and the execution of ambitious cost-saving and cash flow targets warrant a cautious 'hold' recommendation until these factors become clearer. The potential for upside is significant, but the path to realizing it involves considerable execution risk.

Keywords

cannabis market, New York, acquisition, joint venture, cultivation facility, dispensaries, regulatory approval, financing